CN113577179B - Pharmaceutical composition for liver injury protection and application thereof - Google Patents
Pharmaceutical composition for liver injury protection and application thereof Download PDFInfo
- Publication number
- CN113577179B CN113577179B CN202110806228.XA CN202110806228A CN113577179B CN 113577179 B CN113577179 B CN 113577179B CN 202110806228 A CN202110806228 A CN 202110806228A CN 113577179 B CN113577179 B CN 113577179B
- Authority
- CN
- China
- Prior art keywords
- liver
- pharmaceutical composition
- parts
- liver injury
- injury protection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 44
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 32
- 210000003494 hepatocyte Anatomy 0.000 claims abstract description 15
- 230000001737 promoting effect Effects 0.000 claims abstract description 11
- 230000004792 oxidative damage Effects 0.000 claims abstract description 10
- 230000035755 proliferation Effects 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 30
- 239000006286 aqueous extract Substances 0.000 claims description 24
- 210000005229 liver cell Anatomy 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 19
- 240000005373 Panax quinquefolius Species 0.000 claims description 13
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 241001116477 Adenophora triphylla Species 0.000 claims description 12
- 244000307697 Agrimonia eupatoria Species 0.000 claims description 12
- 244000274050 Platycodon grandiflorum Species 0.000 claims description 11
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 10
- 235000000125 common agrimony Nutrition 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 230000005779 cell damage Effects 0.000 claims description 3
- 208000037887 cell injury Diseases 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 241000726221 Gemma Species 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 244000061520 Angelica archangelica Species 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 39
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract description 34
- 241000700159 Rattus Species 0.000 description 59
- 210000004185 liver Anatomy 0.000 description 26
- 210000002966 serum Anatomy 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 13
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 241000125175 Angelica Species 0.000 description 8
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 description 8
- 108010012715 Superoxide dismutase Proteins 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000005228 liver tissue Anatomy 0.000 description 8
- 229940118019 malondialdehyde Drugs 0.000 description 8
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 7
- 229960002591 hydroxyproline Drugs 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 7
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 239000003613 bile acid Substances 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241000382455 Angelica sinensis Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 3
- 241000357613 Platycodon Species 0.000 description 3
- 235000006751 Platycodon Nutrition 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 210000004024 hepatic stellate cell Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 229930189914 platycodon Natural products 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 3
- 229960004245 silymarin Drugs 0.000 description 3
- 235000017700 silymarin Nutrition 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 235000016993 Agrimonia Nutrition 0.000 description 2
- 241000244987 Daiswa polyphylla Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241001633583 Adenophora Species 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 208000015163 Biliary Tract disease Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 1
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 1
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 230000005813 organ abnormality Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229930189407 platycodin Natural products 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- -1 radix bupleuri Chemical compound 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930183842 salvianolic acid Natural products 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of medicines, and relates to a pharmaceutical composition for liver injury protection and application thereof. The invention provides a pharmaceutical composition for liver injury protection, which has good activity of promoting hepatocyte proliferation, activity of relieving oxidative damage of hepatocytes and activity of resisting hepatic fibrosis, and an application thereof.
Description
Technical Field
The invention belongs to the field of medicines, relates to a pharmaceutical composition and application thereof, and particularly relates to a pharmaceutical composition for protecting liver injury and application thereof.
Background
Chronic liver disease is a disease with high worldwide morbidity and mortality. Hepatic fibrosis is a histopathological change caused by various acute or chronic liver diseases, such as viral hepatitis B or C, non-alcoholic fatty liver disease, alcoholic steatohepatitis, non-alcoholic steatohepatitis, biliary tract diseases, cholestatic liver diseases and the like. Liver damage leads to hyperactivity of Hepatic Stellate Cells (HSCs) and thus triggers increased extracellular matrix (ECM) synthesis, excessive collagen fibers are deposited in the extracellular space of hepatocytes, resulting in loss of blood supply to hepatocytes, which may further progress to cirrhosis and even liver cancer if proper attention and treatment is not given. It is a reversible scarring response, with nodule formation and organ retraction as important features, and almost all chronic liver diseases can cause liver fibrosis. Fortunately, the process of liver fibrosis is reversible and intervention at even advanced stages of cirrhosis can improve clinical outcome. At present, the treatment principle of hepatic fibrosis is to remove etiology and diminish inflammation, and the treatment strategy is to prevent HSCs (human hematopoietic stem cells) activation, collagen degradation and drug-targeted therapy, but no specific medicine is available for treating hepatic fibrosis at present. The traditional Chinese medicine has the characteristics of treatment based on syndrome differentiation and overall view, and has unique advantages in the aspect of anti-hepatic fibrosis.
According to the traditional Chinese medicine, the liver fibrosis belongs to the category of liver accumulation, and the liver fibrosis is formed by qi stagnation and blood stasis caused by deficiency of healthy qi and then invasion of pathogenic qi (Yi Zong Bi Shu), which is mostly caused by deficiency of healthy qi and six exogenous factors. The "the disease origin and disease symptoms" refers to the feature of the disease persisting for a long time. Therefore, liver injury can be caused by deficiency of healthy qi, damp-heat evil toxin, qi and blood stasis and the like, the traditional Chinese medicine is mainly used for treating diseases by strengthening healthy qi to eliminate pathogenic factors, and heavily activating blood and dissolving stasis when eliminating pathogenic factors, and dialectical administration is carried out by treatment methods of tonifying qi and yin, clearing damp-heat, activating blood and dissolving stasis and the like. Modern researches report that a plurality of Chinese herbal medicines have the effects of resisting hepatic fibrosis and viruses, relieving liver cell injury, repairing damaged liver cells, reducing transaminase and the like. Such as salvianolic acid, total glucosides of paeony, silymarin, radix bupleuri, astragaloside, astragalus polysaccharide, matrine, baicalin, rhein, angelica polysaccharide, deoxyschizandrin, panax notoginseng saponins, curcumin and the like, can relieve liver cell and tissue damage, repair damaged liver cells, promote regeneration of the damaged liver cells, improve inflammation, effectively reduce transaminase and restore liver function, and part of related preparations also have the effects of resisting hepatic fibrosis and viruses. The traditional Chinese medicine can be used by compatibility of medicines, has the effects of attenuation and synergism, plays the characteristics of multi-component, multi-target and multi-channel intervention on diseases, and has a certain effect of relieving chronic injuries and diseases needing long-term administration, so that the current research focuses on researching the action mechanism of protecting liver injuries, particularly reversing hepatic fibrosis, intervening and relieving liver cirrhosis, searching new treatment targets and developing novel medicines for treating liver injuries and having high safety.
Disclosure of Invention
In order to solve the technical problems in the background art, the invention provides a pharmaceutical composition for liver injury protection, which has good activity of promoting hepatocyte proliferation, activity of alleviating oxidative damage of hepatocytes and activity of resisting hepatic fibrosis, and an application thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
a pharmaceutical composition for liver injury protection, characterized by: the pharmaceutical composition for protecting liver injury is prepared from raw material medicines of American ginseng, hairyvein agrimonia herb and bud, Chinese angelica, paris rhizome, adenophora tetraphylla and platycodon grandiflorum.
The pharmaceutical composition for protecting liver injury is prepared from 20-30 parts of American ginseng, 20-30 parts of hairyvein agrimony, 10-20 parts of angelica sinensis, 10-20 parts of rhizoma paridis, 10-20 parts of adenophora tetraphylla and 10-20 parts of platycodon grandiflorum, and preferably, the pharmaceutical composition for protecting liver injury is prepared from 20 parts of American ginseng, 30 parts of hairyvein agrimony, 10 parts of angelica sinensis, 15 parts of rhizoma paridis, 15 parts of adenophora tetraphylla and 10 parts of platycodon grandiflorum.
An aqueous extract of a liver injury protecting pharmaceutical composition prepared based on the liver injury protecting pharmaceutical composition as described above.
A method of preparing an aqueous extract as hereinbefore described, the method comprising the steps of:
1) weighing radix Panacis Quinquefolii, herba et Gemma Agrimoniae, radix Angelicae sinensis, rhizoma paridis, radix Adenophorae and radix Platycodi according to the ratio of raw materials to obtain a raw material mixture;
2) decocting the mixture of the raw materials for 3 times, adding 10 times of water each time, decocting for 1.5 hours for the first two times and 1 hour for the third time, mixing the water decoctions, vacuum concentrating at 60 deg.C under reduced pressure to obtain soft extract with relative density of 1.05-1.15, spray drying, collecting fine powder and all medicinal powder adhered to the inner wall of spray dryer, and mixing to obtain water extract.
Use of an aqueous extract of a pharmaceutical composition for liver injury protection as hereinbefore described in the preparation of a medicament for liver injury protection.
Use of an aqueous extract of a pharmaceutical composition for liver injury protection as described above for the preparation of a medicament with hepatocyte proliferation promoting activity.
Use of an aqueous extract of a pharmaceutical composition for liver injury protection as hereinbefore described in the manufacture of a medicament active in reducing liver cell injury.
Use of an aqueous extract of a pharmaceutical composition for liver injury protection as hereinbefore described in the manufacture of a medicament active in reducing oxidative damage to hepatocytes.
The application of the aqueous extract of the pharmaceutical composition for protecting liver injury in preparing the anti-hepatic fibrosis medicine is disclosed.
The application of the aqueous extract of the pharmaceutical composition for protecting liver injury in preparing a medicament for relieving liver fibrosis.
The invention provides a pharmaceutical composition for protecting liver injury and application thereof, the pharmaceutical composition is composed of 6 medicines of American ginseng, hairyvein agrimony, adenophora tetraphylla, angelica, paris polyphylla and platycodon grandiflorum, and has the effects of strengthening body resistance and body resistance, strengthening body resistance and detoxifying, generating blood and stopping bleeding and the like, so the pharmaceutical composition is named as a 'body resistance prescription'. The traditional Chinese and western ginseng and the adenophora tetraphylla have the effects of tonifying qi and yin, tonifying vital qi, clearing away heat and toxic materials, enriching blood and activating blood, and eliminating phlegm and discharging pus. In addition, modern pharmacological studies show that compounds such as ginsenoside in American ginseng, angelica polysaccharide in angelica, platycodon polysaccharide, platycodin and adenophora polysaccharide in platycodon root have the effect of protecting liver, and hairyvein agrimonia herb and bud, platycodon root and rhizoma paridis have the effects of oxidation resistance and inflammation resistance. The invention discovers that the positive source formula has obvious proliferation promoting effect on normal human liver cells and uses hydrogen peroxide H2O2Inducing L02 liver cells to cause an oxidative damage model, and finding a positive source to H after administration2O2The damaged liver cells have a protective effect; by the action of the invention, the rat liver cell fatty degeneration phenomenon is obviously reduced, the number of fibroblasts and lymphocytes is reduced, the collagen deposition amount is reduced, and the liver fibrosis degree of the rat is greatly reduced, which shows that each dose group of the normal prescription has obvious repair effect on liver fibrosisGood anti-hepatic fibrosis activity, and is expected to be developed into new drugs for anti-hepatic fibrosis and liver injury protection.
Drawings
FIG. 1 is a histogram of the survival rate of L02 cells obtained in example 2;
FIG. 2 shows the positive source-side pair H of different concentrations in example 32O2Histogram of protective effects of induced oxidative damage to L02 hepatocytes;
FIG. 3 is a graph showing the results of Hoechst 33342/PI fluorescent staining in example 3;
FIG. 4 is a graph showing the change in body mass of rats with liver fibrosis in example 4;
FIG. 5 is a graph showing the liver/body mass ratio of liver fibrosis rats in example 4;
FIG. 6 is a graph of spleen/body weight ratio of liver fibrosis rats in example 4;
FIG. 7 is a schematic view of H & E, Masson staining of a pathological section in example 5;
FIG. 8 is a graph showing the results of the levels of glutamic-pyruvic transaminase, glutamic-oxalacetic transaminase and alkaline phosphatase in the liver fibrosis rats of example 6;
FIG. 9 is a graph showing the results of the levels of total serum protein and albumin in rats with liver fibrosis in example 7;
FIG. 10 is a graph showing the results of the total bile acid level in the serum of the liver fibrosis rat in example 8;
FIG. 11 is a graph showing the results of the total SOD level in liver tissues of liver fibrosis rats in example 9;
FIG. 12 is a graph showing the results of the malondialdehyde level in liver tissue of liver fibrosis rats in example 10;
FIG. 13 is a graph showing the results of the levels of hydroxyproline in serum from rats in liver fibrosis according to example 11;
FIG. 14 is a graph showing the results of the TGF-. beta.1 level in the serum of rats having liver fibrosis in example 12;
FIG. 15 is a graph showing the results of the serum TNF- α levels in rats with liver fibrosis according to example 13.
Detailed Description
The patent number 201310071107.0 issued by the applicant in 2013 and examined and authorized by the applicant is named as' a radiation-resistant productCompound medicine with protective effect, and provides a patent of compound medicine for resisting nuclear radiation protection60The influence of blood deficiency mice caused by Co ray radiation proves that the medicine for protecting the nuclear radiation damage can effectively protect the damage of the reproductive system of the hematopoietic system box caused by the nuclear radiation and improve the immunity. Through years of research, the original compound medicine formula is optimized, and the existing traditional Chinese medicine compound composition original source formula which is prepared from American ginseng, hairyvein agrimony, adenophora tetraphylla, angelica, rhizoma paridis and platycodon grandiflorum is determined. The research of the invention finds that the pharmaceutical composition has the function of promoting the proliferation of the normal human liver cells L02 and the function of resisting the oxidative damage of the liver cells, and preliminarily deduces that the pharmaceutical composition has the liver protection function. Chronic liver injury can cause hepatic fibrosis, and reports that the medicine composition is used for preventing and treating hepatic fibrosis diseases in a positive prescription are not found so far. After long-term experiments by the inventor, the finally obtained pharmaceutical composition for protecting liver injury is prepared from the bulk drugs of 20-30 parts of American ginseng, 20-30 parts of hairyvein agrimony, 10-20 parts of angelica, 10-20 parts of rhizoma paridis, 10-20 parts of adenophora tetraphylla and 10-20 parts of platycodon grandiflorum, and the pharmaceutical composition for protecting liver injury formed in the proportion range has very good or basically equivalent effects.
In order to illustrate the problem, the invention randomly adopts the raw materials of 20 parts of American ginseng, 30 parts of hairyvein agrimony, 10 parts of angelica, 15 parts of rhizoma paridis, 15 parts of adenophora tetraphylla and 10 parts of platycodon grandiflorum to prepare the pharmaceutical composition for protecting liver injury in the range, and carries out relevant tests and verifies the effect. The technical scheme provided by the invention is explained in detail by combining the specific embodiments as follows:
example 1 preparation of a Positive stock aqueous extract
The traditional Chinese medicine composition preparation is prepared from the following raw material medicines in parts by weight: 20 parts of American ginseng, 30 parts of hairyvein agrimony, 10 parts of angelica, 15 parts of rhizoma paridis, 15 parts of adenophora tetraphylla and 10 parts of platycodon grandiflorum, decocting for 3 times, adding 10 times of water each time, decocting for 1.5 hours each time in the first two times, decocting for 1 hour in the third time, combining water decoction liquids decocted for the three times, concentrating under vacuum and reduced pressure at 60 ℃ to obtain thick paste with the relative density of 1.05-1.15, spray drying, collecting fine powder and all medicinal powder adhered to the inner wall of a spray dryer, and mixing uniformly to obtain the water extract of the positive source formula.
The American ginseng adopted by the invention is cool in nature, sweet in taste and slightly bitter, enters heart, lung and kidney channels, and has the effects of tonifying qi and yin, clearing heat and promoting fluid production. The agrimony is neutral in nature and bitter and astringent in taste, and has the effects of astringing to stop bleeding, preventing malaria, stopping dysentery, detoxifying and tonifying deficiency. Chinese angelica root, radix Angelicae sinensis, warm in nature, sweet and pungent in flavor, enters liver, heart and spleen channels, and has the effects of enriching and activating blood, regulating menstruation, relieving pain, moistening intestines and relaxing bowels. Paris polyphylla, with slightly cold nature, bitter taste and little toxicity, enters liver meridian, clears away heat and toxic material, relieves swelling and pain, cools liver and calms convulsion. Adenophora tetraphylla is slightly cold in nature and sweet in taste, enters lung and stomach channels, nourishes yin to clear away the lung-heat, benefits the stomach to promote the production of body fluid, reduces phlegm and benefits qi. Platycodon grandiflorum, neutral in nature, bitter and pungent in taste, enters lung meridian, disperses lung, relieves sore throat, eliminates phlegm and expels pus.
Example 2 Effect of Positive Source formula aqueous extract on the viability of L02 human Normal hepatocytes
L02 cells were cultured at 1.5X 105The density of each/mL is inoculated in a 96-well plate and is kept overnight, the water extract of the positive source prescription is added, the working concentration of the water extract of the positive source prescription in each well is 20, 50, 100, 200, 500 and 1000 mu g/mL, MTT is added after 24h for cell viability measurement, the influence of the water extract of the positive source prescription with different concentrations on the viability of L02 human normal liver cells is measured, a bar chart of the viability of L02 cells is shown in detail in figure 1, the invention finds that the water extract of the positive source prescription is in the range of 100 mu g/mL to 500 mu g/mL, the proliferation promoting effect on human normal liver cells L02 is obvious, and the proliferation promoting effect is obvious at 500 mu g/mL.
Example 3 Positive Source formula aqueous extract vs. H2O2Protective effects of induced oxidative damage to L02 hepatocytes
The results of example 2 were used to screen the range of concentration of the appropriate positive source aqueous extract, further by H2O2Inducing and constructing a liver cell oxidative damage model, determining the survival rate of each group of cells by MTT, and finding that the positive source has obvious proliferation promoting effect on normal human liver cells and hydrogen peroxide H is used for promoting the proliferation of the normal human liver cells2O2Inducing L02 liver cells to cause oxidative damage model, and setting H after concentration exploration2O2Injury was performed at a concentration of 250 μ M, and a positive source was found to be peroxidized after administrationThe hydrogen-damaged liver cells have protective effect. Each group of living cells was stained by Hoechst 33342/PI double staining, the stained cells were observed under Hoechst 33342 fluorescence channel using fluorescence microscope, the total fluorescence number indicates the change of the number of L02 cells, the stained cells were necrotic cells when observed under PI fluorescence channel, and the staining results are shown in detail in FIG. 3. According to the invention, cells are dyed by the Hoechst 33342/PI kit, and the results show that in a bright field, compared with a blank group, the number of the cells in the model group is obviously reduced, the Hoechst 33342 fluorescence image shows that the nuclear matters of the model group are agglutinated and shrunk, which indicates that the liver cells are apoptotic after hydrogen peroxide damage, the PI fluorescence image shows that the cells in the model group have obvious necrotic cells, and the intervention administration of the positive source administration group can relieve the apoptosis and necrosis.
Example 4 Positive Source formula aqueous extract vs CCl4Liver protection effect of induced liver fibrosis rat
Male SD rats were randomly divided into 8 groups: control group, model group, positive source prescription low dose group, positive source prescription medium dose group, positive source prescription high dose group, positive source prescription negative control group, rhizoma paridis negative control group, each group contains 6. Except two negative control groups, the rats of the model group and the administration group are injected with 40 percent CCl in the abdominal cavity4(CCl4: olive oil 2: 3, 1mL/kg), control rats were injected intraperitoneally with an equal amount of olive oil solution 2 times a week for 8 weeks. Silymarin (200mg/kg) was administered to the positive group, and silymarin (1-2, 2-4, 4-6g/kg, in this and the following examples, 1.6 g/kg was administered to the positive low dose group, 3.2g/kg was administered to the medium low dose group, and 4.8g/kg was administered to the high dose group) for 8 weeks once a day. Continuously administering for 2 days after 8 weeks of last molding, fasting, performing abdominal aorta blood sampling after 3 days of anesthesia of all rats, and separating serum; taking a rat liver specimen, fixing the middle part of the left lobe of the liver in 10% paraformaldehyde fixing solution, and carrying out liver histopathological detection; taking specific part of liver, adding 9 times of physiological saline to carry out tissue homogenization, and centrifuging to extract supernatant for later use. The rest liver tissues are stored in a refrigerator at the temperature of 80 ℃ below zero and used for detecting the expression level of the target protein. Continuous monitoring of rat body massThe numerical values are shown in figure 4, and the liver and spleen organ indexes of each group are shown in figure 5 and figure 6. As can be seen from FIGS. 5 and 6, compared with the blank group, the liver and spleen organ indexes of the rats in the model group are both obviously increased, which indicates that the liver and spleen organ indexes of the rats in the model group are abnormal, and the liver and spleen organ indexes of the rats in the administration group are obviously reduced compared with those of the rats in the model group, which indicates that the water extract of the vital prescription has a certain improvement effect on the liver and spleen organ abnormality induced by carbon tetrachloride.
Example 5 Effect of Positive Source Water extract on improving degree of liver fibrosis in rat
As can be seen from the staining result of H & E, Masson in FIG. 7, the rat hepatocytes of hepatic fibrosis induced by carbon tetrachloride showed large-area steatosis, the pseudolobular structure was significantly increased, fibroblasts and lymphocytes were increased, and the number of collagen fibers was increased. The results show that: compared with a blank group, the model group has the phenomena of large-area hepatic cell fatty vacuole degeneration, fibroblast increase and lymphocyte increase; compared with the blank group, the collagen deposition quantity of the model group is obviously increased; and thirdly, the appearance of the normal liver of the rats in the blank group is red, the color of the liver of the rats in the model group is abnormal, and the surface of the rats is obviously hepatic fibrosis. The fat degeneration phenomenon of liver cells of rats in the administration group is obviously reduced, the number of fibroblasts and lymphocytes is reduced, the deposition amount of collagen is reduced, and the hepatic fibrosis degree of rats is greatly reduced, which shows that each dose group of the positive origin formula has obvious repair effect on hepatic fibrosis. The results show that the medicine composition is a positive source prescription, has good anti-hepatic fibrosis activity, and is expected to be developed into a new anti-hepatic fibrosis medicine.
Example 6 Effect of Positive-origin aqueous extracts on serum levels of glutamic-pyruvic transaminase, glutamic-oxaloacetic transaminase and alkaline phosphatase in liver fibrosis rats
Alanine Aminotransferase (ALT), aspartate Aminotransferase (AST) and alkaline phosphatase (ALP) are metabolic enzymes of the liver, and are indexes for clinical examination of liver injury. The expression levels of alanine Aminotransferase (ALT), aspartate Aminotransferase (AST) and alkaline phosphatase (ALP) in the serum of each rat group were measured using a full-automatic biochemical analyzer (Mindray, BS-330E). As can be seen from FIG. 8, consistent with the results of example 5, ALT, AST and ALP levels in serum of the administered group were all decreased compared with rats with hepatic fibrosis induced by carbon tetrachloride, which indicates that the hepatic fibrosis degree of the rats was significantly reduced after administration of the positive source aqueous extract.
Example 7 Effect of Positive Source Water extracts on serum Total protein, Albumin levels in rats with hepatic fibrosis
The expression levels of Total Protein (TP) and Albumin (ALB) in the serum of each rat group were measured using a fully automated biochemical analyzer (Mindray, BS-330E). As can be seen from fig. 9, both model TP and ALB levels were down-regulated compared to the blank control group. Compared with the model group, the TP level of the administration group is up-regulated, and the ALB level has no significant difference.
Example 8 Effect of Positive Source formula Water extracts on Total Cholesterol levels in serum from rats with hepatic fibrosis
Total Bile Acid (TBA) is a catabolic product of cholesterol in the liver, is secreted into bile by the liver and is discharged into an intestinal cavity along with the bile, acts on the digestion and absorption of fat, the generation and metabolism of the bile acid are closely related to the liver, and when liver cells are diseased, the serum total bile acid is easy to increase, and is a sensitive diagnostic index for detecting substantial liver injury. The expression level of Total Bile Acid (TBA) in the serum of each group of rats was measured using a fully automated biochemical analyzer (Mindray, BS-330E). The result shows that the TBA level of the model group is obviously increased compared with that of a blank control group, and compared with the model group, the positive source formula water extract administration group obviously reduces the TBA level, which indicates that the liver cells of rats in the model group are damaged and the metabolism of the liver function is abnormal, and the positive source formula administration group can reduce the damage degree of the liver.
Example 9 Effect of Positive stock Water extracts on Total superoxide dismutase levels in liver tissue of liver fibrosis rats
The total superoxide dismutase (SOD) level in rat liver tissue is measured by adopting a total superoxide dismutase detection kit (Nanjing Biotechnology Co., Ltd.), and the result shows that the SOD level of a model group is obviously reduced compared with that of a blank group, and compared with the model group, the SOD level of a positive source prescription administration group is obviously increased.
Example 10 Effect of Positive Source Water extracts on the level of malondialdehyde in liver tissue of liver fibrosis rats
The malondialdehyde detection kit (Nanjing Biotechnology Ltd.) is adopted to determine the level of Malondialdehyde (MDA) in rat liver tissues, and the results show that compared with a blank rat group, the MDA level in rat liver tissues of a hepatic fibrosis model group is obviously up-regulated, and an orthologous administration group is obviously down-regulated to abnormally increased MDA level of the model group. The results of example 9, combined with the analysis, show that the aqueous extract of the positive source has the function of reducing the oxidative stress level caused by hepatic fibrosis due to carbon tetrachloride. The results of the tests in example 9 and example 10 are mutually verified, which shows that the model group has oxidation damage phenomenon compared with the blank group, and the administration group can reverse the abnormal SOD and MDA levels in the model group, thus demonstrating that the positive source has certain effect on improving the liver oxidation damage.
Example 11 Effect of Positive Source Water extracts on serum hydroxyproline levels in rats with hepatic fibrosis
Hydroxyproline is an index for testing hepatic fibrosis degree, and Hydroxyproline (HYP) expression level in each group of rat serum is determined by hydroxyproline detection kit (Nanjing to Biotech limited). As can be seen from fig. 13, consistent with the results of example 5, fibrosis was relatively reduced and HYP levels in serum were significantly reduced after orthogenic administration compared to hepatic fibrosis rats.
Example 12 Effect of Positive Source Water extracts on serum TGF-beta 1 levels in rats with liver fibrosis
TGF-beta 1 enzyme-linked immunosorbent assay detection kit (Xinbo Sheng Biotechnology Co., Ltd.) is adopted to carry out in-vitro quantitative determination on the expression level of TGF-beta 1 in the serum of each group of rats. As can be seen from FIG. 14, consistent with the results of example 5, TGF- β 1 levels were significantly reduced in rats after administration of low and medium doses in a positive prescription, compared to hepatic fibrosis rats. TGF-beta 1 is transforming growth factor beta 1, and the key function is adjusting inflammation process, the experimental result shows that compared with the blank group, the TGF-beta 1 level in the blood serum of the hepatic fibrosis rat is obviously increased, and the TGF-beta 1 level in the model group can be obviously reduced by the positive group, the positive source prescription low and medium dosage administration group.
Example 13 Effect of Positive Source Water extracts on serum TNF- α levels in rats with liver fibrosis
The expression level of TNF-alpha in each group of rat serum was quantitatively determined in vitro by TNF-alpha enzyme-linked immunosorbent assay kit (Xinbo Sheng Biotech Co., Ltd.). The TNF-alpha is tumor necrosis factor alpha and is a cytokine related to systemic inflammation, and experimental results show that compared with a blank group, the TNF-alpha level in the serum of a hepatic fibrosis rat is obviously increased, and the TNF-alpha level in a model group can be obviously reduced by a positive group and a low-dose administration group of a positive source prescription, which shows that the positive source prescription has a certain effect on improving the inflammation level of the hepatic fibrosis. As can be seen from FIG. 15, consistent with the results of example 5, TNF-. alpha.levels were significantly down-regulated in rats after administration of low dose of the positive-source formulation compared to liver fibrosis rats.
The experimental results show that the positive source has a certain effect of anti-hepatic fibrosis on the level of animals from the aspects of body weight change, organ index, serum biochemical index, oxidation index and inflammatory index.
Claims (10)
1. A pharmaceutical composition for liver injury protection, characterized by: the pharmaceutical composition for protecting liver injury is prepared from the following raw materials of 20-30 parts of American ginseng, 20-30 parts of hairyvein agrimony, 10-20 parts of angelica, 10-20 parts of rhizoma paridis, 10-20 parts of adenophora tetraphylla and 10-20 parts of platycodon grandiflorum.
2. The pharmaceutical composition for liver injury protection according to claim 1, characterized in that: the pharmaceutical composition for protecting liver injury is prepared from the following raw materials of 20 parts of American ginseng, 30 parts of hairyvein agrimony, 10 parts of angelica, 15 parts of rhizoma paridis, 15 parts of adenophora tetraphylla and 10 parts of platycodon grandiflorum.
3. An aqueous extract of a pharmaceutical composition for liver injury protection prepared based on the pharmaceutical composition for liver injury protection of claim 1 or 2.
4. A process for the preparation of an aqueous extract according to claim 3, characterized in that: the preparation method comprises the following steps:
1) weighing radix Panacis Quinquefolii, herba et Gemma Agrimoniae, radix Angelicae sinensis, rhizoma paridis, radix Adenophorae and radix Platycodi according to the ratio of raw materials to obtain a raw material mixture;
2) decocting the mixture of the raw materials for 3 times, adding 10 times of water each time, decocting for 1.5 hours for the first two times and 1 hour for the third time, mixing the water decoctions, vacuum concentrating at 60 deg.C under reduced pressure to obtain soft extract with relative density of 1.05-1.15, spray drying, collecting fine powder and all medicinal powder adhered to the inner wall of spray dryer, and mixing to obtain water extract.
5. Use of an aqueous extract of the pharmaceutical composition for liver injury protection according to claim 3 for the preparation of a medicament for liver injury protection.
6. Use of an aqueous extract of the pharmaceutical composition for liver injury protection of claim 3 for the preparation of an active drug for promoting hepatocyte proliferation.
7. Use of an aqueous extract of the pharmaceutical composition for liver injury protection according to claim 3 for the preparation of an active agent for alleviating liver cell injury.
8. Use of an aqueous extract of the pharmaceutical composition for liver injury protection according to claim 3 for the preparation of an active agent for alleviating oxidative damage to hepatocytes.
9. Use of an aqueous extract of the pharmaceutical composition for liver injury protection according to claim 3 for the preparation of an anti-liver fibrosis medicament.
10. Use of an aqueous extract of the pharmaceutical composition for liver injury protection according to claim 3 for the preparation of a medicament for reducing liver fibrosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110806228.XA CN113577179B (en) | 2021-07-16 | 2021-07-16 | Pharmaceutical composition for liver injury protection and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110806228.XA CN113577179B (en) | 2021-07-16 | 2021-07-16 | Pharmaceutical composition for liver injury protection and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113577179A CN113577179A (en) | 2021-11-02 |
| CN113577179B true CN113577179B (en) | 2022-05-06 |
Family
ID=78247853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110806228.XA Active CN113577179B (en) | 2021-07-16 | 2021-07-16 | Pharmaceutical composition for liver injury protection and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113577179B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114470042B (en) * | 2022-03-18 | 2023-09-05 | 四川农业大学 | Composition for preventing and treating liver injury of animals as well as preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101708272A (en) * | 2009-12-30 | 2010-05-19 | 河南中医学院 | Chinese medicament for treating liver cancer |
| CN102512485A (en) * | 2011-12-31 | 2012-06-27 | 陕西中医学院 | Traditional Chinese medicine for treating acute hepatitis, chronic hepatitis and hepatic fibrosis |
| CN103169843A (en) * | 2013-03-06 | 2013-06-26 | 唐俊琪 | Compound medicine having radiation resisting and protecting effects |
-
2021
- 2021-07-16 CN CN202110806228.XA patent/CN113577179B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101708272A (en) * | 2009-12-30 | 2010-05-19 | 河南中医学院 | Chinese medicament for treating liver cancer |
| CN102512485A (en) * | 2011-12-31 | 2012-06-27 | 陕西中医学院 | Traditional Chinese medicine for treating acute hepatitis, chronic hepatitis and hepatic fibrosis |
| CN103169843A (en) * | 2013-03-06 | 2013-06-26 | 唐俊琪 | Compound medicine having radiation resisting and protecting effects |
Non-Patent Citations (6)
| Title |
|---|
| Design, Preparation, and Characterization of Dioscin Nanosuspensions and Evaluation of Their Protective Effect against Carbon Tetrachloride-Induced Acute Liver Injury in Mice;Hong-ye Ju，等;《Evid Based Complement Alternat Med》;20191114(第11期);第1-16页 * |
| 参桃软肝丸含药血清对HepG-2细胞凋亡及细胞周期影响的实验研究;梁艳菊，等;《中医临床研究》;20131231;第5卷(第12期);第7-8页 * |
| 基于环磷酰胺致小鼠损伤保护作用研究正源方前处理工艺;程晓妮，等;《中南药学》;20210930;第19卷(第9期);第1822-1827页 * |
| 正源方对免疫性血小板减少性紫癜小鼠的影响;曲永红，等;《中药药理与临床》;20140415;第30卷(第02期);第124-128页 * |
| 正源方对环磷酰胺所致豚鼠骨髓抑制的保护作用研究;曲永红，等;《西北药学杂志》;20140228;第29卷(第2期);第148-152页 * |
| 正源方干预化疗后白细胞减少症的网络药理学研究及实验验证;张君威，等;《中草药》;20211031;第52卷(第21期);第6586-6597页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113577179A (en) | 2021-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Research progress in the treatment of slow transit constipation by traditional Chinese medicine | |
| US6696094B2 (en) | Herbal pharmaceutical composition for treatment of HIV/AIDS patients | |
| CN101721488B (en) | Pharmaceutical composition for treating liver diseases and prepration method thereof | |
| Shao et al. | Screening of the optimized prescription from Suqingwan in terms of its therapeutic effect on DSS-induced ulcerative colitis by its regulation of inflammatory and oxidative mediators | |
| CN113577179B (en) | Pharmaceutical composition for liver injury protection and application thereof | |
| CN110025699A (en) | Yi nationality's medicine compound, active principle composition and its application with myocardium protecting action | |
| CN107693571B (en) | Traditional Chinese medicine composition and preparation for preventing or treating hepatic fibrosis and liver cirrhosis and preparation method of preparation | |
| Zhang et al. | Mechanisms of NLRP3 inflammasome in rheumatoid arthritis and osteoarthritis and the effects of traditional Chinese medicine | |
| CN101773490B (en) | Active part of Sambucus williamsii Hance for reducing risk of bone-related diseases of menopausal women and application thereof | |
| Zhi et al. | Therapeutic potential of Angelica sinensis in addressing organ fibrosis: A comprehensive review | |
| CN104435977B (en) | It is a kind of to be used to treat medicine of hepatic injury and preparation method thereof | |
| CN103933386B (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN101698085B (en) | Medicine composite for treating early liver fibrosis or early hepatocirrhosis decompensation, preparation method and application | |
| CN108355124B (en) | Traditional Chinese medicine composition for treating airway mucus hypersecretion and application thereof | |
| CN104095912B (en) | Treat the preparation method of the Chinese patent drug of rheumatism bone disease | |
| CN112603983A (en) | Pharmaceutical composition for treating COPD (chronic obstructive pulmonary disease) with pulmonary fibrosis | |
| CN102058825B (en) | Traditional Chinese medicinal composition for treating hepatitis and preparation method thereof | |
| Jiang et al. | Traditional Chinese medicine for the treatment of immune-related nephropathy: A review | |
| CN110368434B (en) | Compound valerian medicine for treating chronic renal failure and its prepn | |
| CN112386671B (en) | Traditional Chinese medicine composition for treating interstitial lung disease and application thereof | |
| CN112138105B (en) | Traditional Chinese medicine composition for treating bronchiectasis lung-spleen qi deficiency and phlegm-damp lung blocking syndrome and application thereof | |
| CN111494508B (en) | Preparation method of traditional Chinese medicine gout plaster and product thereof | |
| CN112402566B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating gonarthromeningitis | |
| CN107233427B (en) | Traditional Chinese medicine composition for preventing and treating postmenopausal osteoporosis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |